Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

NCT02289690 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Veliparib
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Placebo

Sponsor

AbbVie